Abstract
Rheumatoid arthritis (RA) is a chronic erosive inflammatory disease which can involve the locomotor system and cause systemic involvement. The efficacy and safety of anti-TNF-alpha drugs have been shown in active RA cases that are resistant to traditional disease-modifying antirheumatic drugs. However, it is well known that anti-TNF-alpha drugs may cause lymphomas and various solid malignancies. On the other hand, there are studies on the efficacy of anti- TNF-alpha drugs in the treatment of resistant renal cell cancer. This case report presents a 57-year-old female patient with hematuria who had been followed up with the diagnosis of RA for 20 years and had been using adalimumab for the last 4 years. A solid mass was found in the left kidney in the abdominal ultrasonography and computed tomography. Nephrectomy was performed by general surgery. Histopathological findings of the specimen were consistent with renal cell carcinoma.
Keywords: Adalimumab, renal cell carcinoma, rheumatoid arthritis.
Current Drug Safety
Title:Renal Cell Carcinoma in a Patient with Rheumatoid Arthritis Treated with Adalimumab
Volume: 9 Issue: 1
Author(s): Senol Kobak, Ahmet Karaarslan and Yunus Aktakka
Affiliation:
Keywords: Adalimumab, renal cell carcinoma, rheumatoid arthritis.
Abstract: Rheumatoid arthritis (RA) is a chronic erosive inflammatory disease which can involve the locomotor system and cause systemic involvement. The efficacy and safety of anti-TNF-alpha drugs have been shown in active RA cases that are resistant to traditional disease-modifying antirheumatic drugs. However, it is well known that anti-TNF-alpha drugs may cause lymphomas and various solid malignancies. On the other hand, there are studies on the efficacy of anti- TNF-alpha drugs in the treatment of resistant renal cell cancer. This case report presents a 57-year-old female patient with hematuria who had been followed up with the diagnosis of RA for 20 years and had been using adalimumab for the last 4 years. A solid mass was found in the left kidney in the abdominal ultrasonography and computed tomography. Nephrectomy was performed by general surgery. Histopathological findings of the specimen were consistent with renal cell carcinoma.
Export Options
About this article
Cite this article as:
Kobak Senol, Karaarslan Ahmet and Aktakka Yunus, Renal Cell Carcinoma in a Patient with Rheumatoid Arthritis Treated with Adalimumab, Current Drug Safety 2014; 9 (1) . https://dx.doi.org/10.2174/15748863113086660063
DOI https://dx.doi.org/10.2174/15748863113086660063 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Recombinant T Cell Receptor Strategy: Insights into Structure and Function of Recombinant Immunoreceptors on the Way Towards an Optimal Receptor Design for Cellular Immunotherapy
Current Gene Therapy Equilibrative Nucleoside Transporters in Fetal Endothelial Dysfunction in Diabetes Mellitus and Hyperglycaemia
Current Vascular Pharmacology The Emerging Role of Sunitinib in the Treatment of Advanced Epithelial Thyroid Cancer: Our Experience and Review of Literature
Mini-Reviews in Medicinal Chemistry Drug Delivery Systems Based on Polymeric Micelles and Ultrasound: A Review
Current Pharmaceutical Design Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction
Current Pharmaceutical Design Pulmonary Hypertension and Systemic Diseases
Current Drug Targets - Inflammation & Allergy Progress in the Development of Aminopeptidase N (APN/CD13) Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors
Current Pharmaceutical Design Zebrafish as a Model System to Screen Radiation Modifiers
Current Genomics ICH/FDA Guidelines-Compliant Validated Stability-Indicating HPLC-UV Method for the Determination of Axitinib in Bulk and Dosage Forms
Current Analytical Chemistry Urinary Tract Tumors, Biology and Risk for Artificial Sweeteners Use with Particular Emphasis on some South American Countries
Current Nutrition & Food Science Epidermal Growth Factor Receptor as a Target for Anti-Cancer Agent Design
Anti-Cancer Agents in Medicinal Chemistry Sphingolipid Signaling and Hematopoietic Malignancies: To the Rheostat and Beyond
Anti-Cancer Agents in Medicinal Chemistry Cationic Liposomes as Non-viral Vector for RNA Delivery in Cancer Immunotherapy
Recent Patents on Drug Delivery & Formulation Animal Venoms have Potential to Treat Cancer
Current Topics in Medicinal Chemistry Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer
Current Drug Targets HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Current Pharmaceutical Design Modulation of Cellular Response to Anticancer Treatment by Caffeine: Inhibition of Cell Cycle Checkpoints, DNA Repair and More
Current Pharmaceutical Biotechnology Structural Basis of Tetherin Function
Current HIV Research Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Combinatorial Chemistry & High Throughput Screening